首页> 外文期刊>Journal of Immunological Methods >Comparative study of circulating immune complexes quantity detection by three assays--CIF-ELISA, C1q-ELISA and anti-C3 ELISA.
【24h】

Comparative study of circulating immune complexes quantity detection by three assays--CIF-ELISA, C1q-ELISA and anti-C3 ELISA.

机译:通过CIF-ELISA,C1q-ELISA和抗C3 ELISA三种检测方法检测循环免疫复合物数量的比较研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The assessment of the soluble immune complexes (IC) in human sera is traditionally performed by the C1q binding assay. In the present study, a novel method for the quantity of immune complexes was reported. The methodology was based on measuring their deposition on solid-phase C3 binding glycoprotein (CIF), using an enzyme-linked immunosorbent assay. We also used ELISA that employed anti-C3 antibodies to determined the quantity of immune complexes. The three assays were evaluated for their performance characteristics on the same specially prepared samples: 55 normal sera, 99 sera from RA, 88 sera from SLE, and 27 sera from PSS. The results were compared by reference to a common standard-heat aggregated IgG that possesses many activities of immune complexes. Three of the tests used displayed almost the same specificity (over 95%), while their relative sensitivity varied depending on the disease sera tested. The sensitivity of the assays used was recorded highest for C1q ELISA-28.97% of positive sera, followed by CIF-ELISA-19.63% and lowest for anti-C3 ELISA-17.29%. A well-expressed correlation was found between CIF-ELISA and anti-C3 ELISA data (r=0.42), and a week correlation was noted when comparing CIF-ELISA and C1q ELISA IC levels detected (r=0.28). When the correlation coefficients were calculated individually for each disease category, they were clearly different, and that reflected indirectly in different sensitivities of the test for various disease categories. We also found that the results from the simultaneous performance of the tests demonstrated low percentage positive results when three or two assays were used. This is most probably due to the different assay abilities to detect IC with different sizes and composition, which shows that a small part of IC in the tested sera can be detected simultaneously by more than one assay. On the basis of the results obtained, we concluded that optimal screening for IC could be achieved by parallel application of several different methods.
机译:传统上通过C1q结合测定法对人血清中的可溶性免疫复合物(IC)进行评估。在本研究中,报告了一种新的免疫复合物数量的方法。该方法基于使用酶联免疫吸附测定法测量它们在固相C3结合糖蛋白(CIF)上的沉积。我们还使用了采用抗C3抗体的ELISA测定免疫复合物的数量。在相同的特别准备的样品上评估了这三种测定的性能特征:55正常血清,RA的99血清,SLE的88血清和PSS的27血清。通过参考具有多种免疫复合物活性的普通标准热聚集IgG来比较结果。使用的三种测试显示出几乎相同的特异性(超过95%),而它们的相对灵敏度则根据所测试的疾病血清而有所不同。对于阳性血清的C1q ELISA-28.97%,所用测定的灵敏度最高,其次是CIF-ELISA-19.63%,对于抗C3 ELISA-17.29%最低。在CIF-ELISA和抗C3 ELISA数据之间发现表达良好的相关性(r = 0.42),并且在比较检测到的CIF-ELISA和C1q ELISA IC水平时注意到了一周的相关性(r = 0.28)。当针对每种疾病类别分别计算相关系数时,它们显然是不同的,并且间接反映在测试对各种疾病类别的不同敏感性中。我们还发现,当同时使用三个或两个检测方法时,测试同时进行的结果显示出较低的阳性率。这很可能是由于检测不同大小和组成的IC的检测能力不同所致,这表明可以通过一种以上的检测方法同时检测出待测血清中一小部分IC。根据获得的结果,我们得出结论,可以通过并行应用几种不同的方法来实现IC的最佳筛选。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号